Life Sciences

  • October 30, 2026

    Teva, AbbVie To Face Trial Over Niaspan Pay-For-Delay Claims

    Long-running multidistrict litigation over AbbVie and Teva Pharmaceuticals' agreement to delay generic forms of cholesterol drug Niaspan is headed toward trial, after a Pennsylvania federal judge Friday found a genuine dispute over whether their agreement was a pay-to-delay settlement that violated antitrust laws.

  • October 30, 2026

    'Why Would I Deceive You?': Fact-Checking The Holmes Doc

    With former Theranos CEO Elizabeth Holmes' criminal case receiving renewed attention following the recent release of Nathan Fielder and Lance Oppenheim's documentary "You Can See Everything," Law360 answers questions about Holmes' 2022 securities fraud conviction and fact-checks some of the documentary's most talked-about moments.

  • October 30, 2026

    States Say Trump Can't Limit Funding Freeze Injunction

    A coalition of 23 states and the District of Columbia urged a Rhode Island federal court Friday to let them continue challenging a now-rescinded Trump administration directive to "temporarily" withhold their federal funding, arguing a permanent injunction should still be on the table.

  • October 30, 2026

    Massachusetts And Idaho To Vote On Restricting Cannabis

    On Tuesday, voters in Massachusetts and Idaho will consider ballot measures that would roll back or restrict marijuana legalization, marking the first time that all statewide ballot questions on the issue of cannabis are geared toward fighting reform.

  • October 30, 2026

    DEA Begins Registering Hundreds Of Marijuana Dispensaries

    The U.S. Drug Enforcement Administration began registration of more than 900 state-licensed medical marijuana dispensaries across seven states, according to an announcement on Friday by the U.S. Department of Justice, which said applications for manufacturers and distributors would likely require additional review.

  • October 30, 2026

    Pharma Supplier Sues To Undo $52M Minority Stake Deal

    Pharmaceutical ingredient manufacturer Pfanstiehl Holdings Inc. has sued a minority shareholder and its general partner in the Delaware Chancery Court, seeking to unwind a $52.3 million transaction that allegedly transferred a majority economic interest in the shareholder's stake to an unidentified investor without required notice or consent.

  • October 30, 2026

    AGs Seek Final OK For $29.6M Glenmark Price-Fixing Deal

    A coalition of 48 states and territories is asking a Connecticut federal judge to give his final approval to a $29.6 million settlement with Glenmark Pharmaceuticals Ltd. that would end claims that the drugmaker conspired with competitors to inflate prices and allocate markets for generic drugs.

  • October 30, 2026

    Ohio Judge Strikes Down Remainder Of 6-Week Abortion Ban

    An Ohio state judge permanently blocked provisions of the state's "heartbeat law" that were previously under review after the court found that the bill's main feature — its prohibition on abortion after around six weeks of pregnancy — violated the state's constitution.

  • October 30, 2026

    3 Firms Guide Pair Of Biotech IPOs Raising $310M

    Two biotechnology firms began trading on Friday after raising a combined $310 million in their initial public offerings, marking the latest in a wave of biotechs to hit the public markets.

  • October 30, 2026

    $9.1M Fee Award Against ChromaDex Erased By Fed. Circ.

    The Federal Circuit Friday overturned a $9.1 million attorney fee award issued to Elysium Health Inc. stemming from a patent infringement case brought by ChromaDex and Dartmouth College, ruling that a district judge had not gone far enough in his patent eligibility analysis.

  • October 30, 2026

    Botox Exempt From Medicare Price Talks, Judge Rules

    The Centers for Medicare & Medicaid Services can't subject AbbVie's Botox to Medicare price negotiations under the Inflation Reduction Act, a D.C. federal judge held, finding CMS misinterpreted an IRA exclusion concerning biological products derived from human plasma.

  • October 30, 2026

    Judge Won't Free Pierce Atwood Of Investor's Malpractice Suit

    Pierce Atwood LLP failed to win dismissal of a lawsuit from a Ukrainian oligarch who says the firm's advice led to a $1.85 million judgment against him in investor litigation over the liquidation of now-insolvent genetic testing company Pathway Genomics Corp.

  • October 29, 2026

    Judge 'Put Off' By Atty Fee Bid In $59.5M Menstrual App Deal

    A California federal judge said Thursday that he'll give final approval to a $59.5 million settlement resolving class claims over a menstrual tracking app sharing sensitive health data with Google, but he cut the $19 million attorney fee request by 5%, saying counsel is "taking money out of consumers' pockets."

  • October 29, 2026

    Colo. Justices Won't Review Hospital's Injunction Compliance

    The Colorado Supreme Court declined Thursday to take up transgender youth patients' challenge to a Denver judge's ruling that discharged their contempt citation against Children's Hospital Colorado for not resuming providing medical gender-affirming care to transgender adolescents.

  • October 29, 2026

    Fertility Cos. Accused Of Moving Eggs Without Consent

    A national fertility clinic network has been hit with a suit in Los Angeles Superior Court alleging it jeopardized a 50-year-old woman's ability to have a biological child by transporting her frozen eggs across state lines to an automated facility without her permission.

  • October 29, 2026

    Camp Lejeune Plaintiffs Blast 'Absurd' Lone Pine Motion

    Plaintiffs in massive multidistrict litigation over toxic water at the Camp Lejeune military base are urging a North Carolina federal court to reject the federal government's bid for a Lone Pine motion requiring claimants to submit proof of their claims, saying it would delay the litigation by years, if not decades, and cause the plaintiffs' costs to skyrocket.

  • October 29, 2026

    Delaware Chancery Keeps $8.9B R1 RCM Buyout Claim Alive

    The Delaware Chancery Court has ruled that private equity firm TowerBrook Capital Partners LP and health system Ascension Health Alliance must face a stockholder claim challenging healthcare revenue management venture R1 RCM Inc.'s $8.9 billion take-private deal, finding that their joint investment vehicle qualified as a controlling stockholder despite owning less than one-third of the company's voting shares.

  • October 29, 2026

    DOL Finalizes Pharmacy Benefit Manager Fee Disclosure Rule

    The U.S. Department of Labor's employee benefits arm unveiled a final rule Thursday that requires pharmacy benefit managers — which act as intermediaries between drugmakers, pharmacies and insurers — to make new disclosures on their fees and compensation to employer-sponsored group health plans.

  • October 28, 2026

    Product Liability's Regulatory & Legislative Recap So Far

    Over the summer and early fall, lawmakers proposed measures aimed at putting safeguards around the rapidly growing industry of artificial intelligence, as public concerns over its safety climb in tandem. The new nominee to head the U.S. Food and Drug Administration also faced sharp queries over her views on vaccines and birth control.

  • October 28, 2026

    Patients Tell Colo. Justices Hospital Defied Gender Care Order

    Transgender youth patients of Children's Hospital Colorado are challenging a judge's discharge of their contempt citation against the hospital for not resuming the provision of medical gender-affirming care to them, urging Colorado's justices to decide whether the hospital complied with an injunction prohibiting it from refusing to provide the care.

  • October 28, 2026

    Squires Rejects Claim That Merck IP Challenge Was 'Abusive'

    The head of the U.S. Patent and Trademark Office has turned down Pogona LLC's argument that Merck's challenge to a patent on selecting a type of bacteria to use in a vaccine against pneumococcal disease was an "abusive" attack on the patent.

  • October 28, 2026

    Pharma Co. Settles Workers' 401(k) Forfeiture Suit

    Boehringer Ingelheim USA Corp. and workers who accused the pharmaceutical company of misusing forfeitures from an employee 401(k) plan have settled their federal benefits dispute, parties told a Connecticut federal court Wednesday.

  • October 28, 2026

    Sanofi Settles Insulin Pen Antitrust Suit, Avoiding Trial

    Sanofi-Aventis US and a group of drug wholesalers have told a Massachusetts federal judge they have reached a settlement to resolve long-running antitrust litigation alleging that the drugmaker improperly sought to thwart competition for its single-use insulin injector pen.

  • October 28, 2026

    Celgene Defends Dismissal Of Cancer Drug Antitrust Suit

    Bristol-Myers Squibb Co. and its subsidiary Celgene Corp. urged the Second Circuit to uphold the dismissal of health plans' proposed antitrust class action alleging that the drugmaker fraudulently obtained patents for the cancer drug Pomalyst, saying it properly disclosed materials to the patent office and filed valid patent infringement lawsuits against generic-drug makers. 

  • October 28, 2026

    4th Circ. Judge Wary Of NC Abortion Drug Law Challenge

    A Fourth Circuit judge on Wednesday sharply questioned the attorney for a physician challenging North Carolina restrictions on the abortion medication mifepristone, citing case law he said treats federal rules as a "floor and not a ceiling" on what states can require.

Expert Analysis

  • How AI Could Help Judges Spot Their Own Biases

    Author Photo

    In close cases where there’s room for discretion, artificial intelligence could challenge judges’ implicit biases by running counterfactual tests at scale — but any judicial use of such tools would need guardrails, say Arnold Peter at Peter Law and Nancy Rapoport at University of Nevada.

  • 3 Eligibility Rulings Show Risks Of Broad Claim Constructions

    Author Photo

    Several recent decisions from the Federal Circuit, including its ruling in Berkeley v. W.W. Grainger, highlight the importance of identifying the inventive aspects of a patent early in the case so that patentees do not inadvertently read the inventive features out of their own claims, say attorneys at MoFo.

  • 3 Strategies To Reduce AI Sycophancy In Legal Work

    Author Photo

    The tendency of generative artificial intelligence models to tell users what they want to hear can reinforce attorneys’ confirmation bias when testing the strength of arguments, and it can’t simply be prompted away — but a few practices can help mitigate it, says Michael Ott at Ice Miller.

  • DOJ Directive Gives Contractors A Fraud Risk Road Map

    Author Photo

    For government contractors, the 10 factors described in the U.S. Department of Justice's recent corporate fraud enforcement directive function as a de facto scoring rubric for internal audits that mirrors what prosecutors will prioritize, say attorneys at Spencer Fane.

  • Why Inter Partes Reviews May Be On The Rebound

    Author Photo

    Recent inter partes review data shows that rates of referrals and institution rates at the U.S. Patent and Trademark Office are increasing, potentially indicating, among other reasons, that patent challengers are adjusting to the USPTO's policy changes, say attorneys at Sterne Kessler.

  • 2nd Circ. EFAA Ruling Shifts Employer Litigation Strategy

    Author Photo

    In Diaz-Roa v. Hermes Law, the Second Circuit recently held that, under the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act, employers can't carve out nonharassment claims and send them to arbitration, which has implications for discovery, litigation costs and resolution strategy in EFAA-covered disputes, say attorneys at Krevolin Horst.

  • 3rd Circ. Ruling Opens Door For Fraud-On-The-Market Rethink

    Author Photo

    The Third Circuit's recent decision in Ocugen, holding that a stable stock price after publication of restated financials does not prove immateriality, could be a vehicle for the U.S. Supreme Court to overturn the doctrine undergirding certification of securities class actions, says Jonathan Richman at Brown Rudnick.

  • 5 Issues To Watch As Fed. Circ. Hears Moderna Vax IP Case

    Author Photo

    Upcoming oral arguments before the Federal Circuit in Arbutus v. Moderna will test whether patent liability protections for government contractors extend to vaccines distributed to the public, and the resolution of certain questions, such as how to define “for the government,” may be key to the outcome, say attorneys at Honigman.

  • 6 Ways Biotechs Can Manage Double Patenting Rejection Risk

    Author Photo

    The Patent Trial and Appeal Board review panel’s recent rejection of a Sanofi application signals that biotechnology and pharmaceutical companies should now take steps to mitigate the possibility that their patents may be rejected for obviousness-type double patenting based on the existence of applications filed years later, say attorneys at Sterne Kessler.

  • Series

    Being In The Peace Corps Made Me A Better Lawyer

    Author Photo

    When I served in the Peace Corps, the people of the West African village where I was stationed helped me acclimate to my new surroundings and enabled me to develop problem-solving, teamwork and empathy skills that have bolstered my legal practice far beyond the ability to offer technical advice, says Brian Bewley at McGuireWoods.

  • 6th Circ. Spotlights Cannabis Contract Enforceability Risks

    Author Photo

    The Sixth Circuit's recent reversal of a $31.8 million jury verdict against a subsidiary of cannabis giant Curaleaf highlights that state licenses do not necessarily provide the legal foundation needed to enforce contracts in federal court, which is a pattern that appears across many sectors, say attorneys at ArentFox Schiff.

  • Where DOJ's Fraud Directive May Actually Affect Enforcement

    Author Photo

    The U.S. Department of Justice’s recent directive outlining corporate fraud enforcement priorities is mostly a management document instead of a policy, but one part may actually undermine the directive's goals by leading to worse outcomes for organizational defendants and less corporate self-disclosure, says Zachary Warren at Williams & Connolly.

  • Why Vaccine Court Inoculates Drugmakers Against Litigation

    Author Photo

    Most claimants alleging injuries from routine childhood vaccines must complete an administrative compensation proceeding before they can sue in civil court — and recent legislative efforts aimed at weakening vaccine manufacturers' legal protections do not account for the important reasons the existing framework was put in place, say attorneys at Goldman Ismail.

  • What Lawyers Should Know Before Accepting Crypto Payment

    Author Photo

    As clients increasingly request to pay legal fees, retainers and escrow funds using cryptocurrency, lawyers should consider how only a handful of state bar authorities have addressed the issue with varying ethics opinions, as well as the related questions that no authority has yet answered, says attorney Felix Shipkevich.

  • What To Know As State 'Neural Data' Privacy Laws Emerge

    Author Photo

    Attorneys at Goodwin discuss new state laws aimed at regulating consumer data generated from nervous system activity, explain why neurotechnology is attracting state and federal legislators’ attention, and highlight the compliance obligations that industry players should address now.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here